Cargando…

Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors

Chronic myeloid leukemia (CML) has become a chronic disease, for which the chronic phase is manageable with tyrosine kinase inhibitor (TKI) therapy. Patients with optimal responses to TKIs have achieved long‐term survival, and treatment‐free remission (TFR) has since become an additional treatment g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortes, Jorge, Rea, Delphine, Lipton, Jeffrey H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2018
Materias:	Critical Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587857/ https://www.ncbi.nlm.nih.gov/pubmed/30394563 http://dx.doi.org/10.1002/ajh.25342

Ejemplares similares

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
por: Hochhaus, Andreas, et al.
Publicado: (2020)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia
por: Yu, Guopan, et al.
Publicado: (2017)

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
por: Guo, Kai, et al.
Publicado: (2019)

What is treatment free remission in chronic myeloid leukemia?
por: Rea, Delphine, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
por: Bhargava, Pankaj, et al.
Publicado: (2011)

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
por: Wada, Yoshihiro, et al.
Publicado: (2012)

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer
por: Stasi, Irene, et al.
Publicado: (2014)

Relevance of treatment‐free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2021)

Treatment-free remission: A new goal for all chronic phase (CP)-CML patients
por: Rea, Delphine
Publicado: (2018)

Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
por: Wang, Shouzheng, et al.
Publicado: (2019)

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022)

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
por: Arrieta, Oscar, et al.
Publicado: (2020)

Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission
por: Stuckey, Ruth, et al.
Publicado: (2022)

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
por: García-Gutiérrez, Valentín, et al.
Publicado: (2020)

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
por: Chiang, Anne C., et al.
Publicado: (2020)

Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
por: Canet, Jim, et al.
Publicado: (2021)

Comparison of T790M Acquisition After Treatment With First- and Second-Generation Tyrosine-Kinase Inhibitors: A Systematic Review and Network Meta-Analysis
por: Hsieh, Po-Chun, et al.
Publicado: (2022)

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia
por: Ward, Melea A., et al.
Publicado: (2015)

Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors
por: Shacham Abulafia, Adi, et al.
Publicado: (2020)

Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome
por: Piekarska, Agnieszka, et al.
Publicado: (2015)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
por: Chang, Cheng-Yu, et al.
Publicado: (2023)

Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Chai, Chee-Shee, et al.
Publicado: (2020)

Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
por: Huang, Chun-Ta, et al.
Publicado: (2023)

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
por: Breccia, Massimo, et al.
Publicado: (2014)

Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics
por: Carpiuc, Kimbach Tran, et al.
Publicado: (2010)

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
por: Nteliopoulos, Georgios, et al.
Publicado: (2019)

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation
por: Nishimura, Tadashi, et al.
Publicado: (2021)

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors
por: Zulbaran‐Rojas, Alejandro, et al.
Publicado: (2018)

Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
por: Iurlo, Alessandra, et al.
Publicado: (2015)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Lymphoid blast crisis after prolonged treatment‐free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de‐escalation during the COVID‐19 pandemic
por: Avenoso, Daniele, et al.
Publicado: (2021)

Philadelphia Chromosome-Positive De Novo Acute Myeloid Leukemia Treated With Chemotherapy and Second-Generation Tyrosine Kinase Inhibitor
por: Muñoz, Juan D, et al.
Publicado: (2019)

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
por: Nelson, Valerie, et al.
Publicado: (2013)

De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
por: Li, Jing-Wen, et al.
Publicado: (2019)

Systematic literature review of treatments used for adult immune thrombocytopenia in the second‐line setting
por: Bylsma, Lauren C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4epqbk82e8fh1oap289v8ejrf4